Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 115 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $132,000 | -41.1% | 11,069 | -19.7% | 0.00% | – |
| Q4 2021 | $224,000 | -43.0% | 13,779 | -0.1% | 0.00% | -100.0% |
| Q3 2021 | $393,000 | -31.2% | 13,787 | -18.4% | 0.00% | -50.0% |
| Q2 2021 | $571,000 | +33.1% | 16,894 | +19.2% | 0.00% | +100.0% |
| Q1 2021 | $429,000 | -33.4% | 14,170 | +8.9% | 0.00% | -50.0% |
| Q4 2020 | $644,000 | +66.0% | 13,012 | +28.6% | 0.00% | 0.0% |
| Q3 2020 | $388,000 | -13.8% | 10,118 | -2.9% | 0.00% | 0.0% |
| Q2 2020 | $450,000 | +22.0% | 10,423 | -11.6% | 0.00% | 0.0% |
| Q4 2019 | $369,000 | – | 11,795 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |